Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
The ErbB2 (Her2) proto-oncogene encodes a receptor tyrosine kinase, which is frequently amplified and overexpressed in human tumors. ErbB2 provides the target for a novel and effective antibody-based therapy (Trastuzumab/Herceptin) used for the treatment of mammary carcinomas. However, cardiomyopath...
Kaydedildi:
| Yayımlandı: | Proc Natl Acad Sci U S A |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
National Academy of Sciences
2002
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC124392/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12072561/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.122249299 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|